According to the National Institutes of Health, this variant of the Apoe gene is one of the strongest genetic risk factors for Alzheimer’s among individuals of European descent.. As one of its first ...

Muna Therapeutics and GSK said they will collaborate to identify and validate new therapeutic targets for Alzheimer’s disease, a step that could pave the way for new treatments for the condition. The ...

Most patients who took foralumab nasal spray for at least six months as part of an expanded use program for nonactive secondary progressive MS saw a reduction in microglia activity in the brain.

The global Phase 2b/3 trial, called Anavex 2-73-AD-004 (NCT03790709), enrolled 509 people, ages 60-85, with mild cognitive impairments or mild dementia due to Alzheimer’s.The participants were ...

C2N, which sponsored the recent study, believes those findings offer robust real-world evidence that blood biomarker testing in the clinic helps to guide treatment decisions and improve patient care..

On-demand treatment with BXCL501, an orally dissolving film formulation of dexmedetomidine, significantly eased episodes of agitation among Alzheimer’s disease patients in a Phase 3 clinical trial, ...

“Results of our open-label proof-of-concept study with COYA 301 in 8 patients with Alzheimer’s showed encouraging results,” Howard Berman, PhD, Coya’s CEO, said in an emailed statement to Alzheimer’s ...

The findings expand on data from a completed Phase 2a trial (NCT05074498) that preceded the OLE (NCT05476783) that showed a month of TB006 improved clinical signs, but failed to reach statistical ...

That’s according to top-line data from the open-label Phase 2 study (NCT04388254) in 216 people with mild-to-moderate disease, treated with simufilam tablets at 100 mg twice daily for a year.. A ...

The trial also met key secondary goals, with lecanemab outperforming placebo at reducing plaque levels and on other measures of disease severity, namely the Alzheimer’s Disease Assessment ...

Before she had Alzheimer’s disease, my mother relished being the first to handle the morning newspaper, and getting her hands on a good magazine was a treat she enjoyed.But as her disease progressed, ...

Consider the following before gently correcting your loved one: The present stage of dementia and your loved one’s ability to process information.; Is the behavior connected to dementia, or was it ...